3 results
Primary objectiveEvaluation of [18F]MC225 to measure the P-glycoprotein function in Alzheimer*s disease, Mild Cognitive Impairment and Parkinson*s disease. Secondary objectives1. Evaluation of blood-brain barrier integrity using [18F]MC225 and MRI…
Safety Run-in (SRI) part:To confirm the recommended phase 2 dose (RP2D) of NIS793 or any other investigational drug(s), in combination with SOC anti-cancer therapy. In protocol amendment 1, an arm with tislelizumab has been added. In this arm, the…
The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line mPDAC.This study aims to explore whether blockade of Transforming…